<DOC>
	<DOCNO>NCT01186458</DOCNO>
	<brief_summary>The purpose study determine effectiveness fludarabine , Velcade , rituximab treatment regimen patient relapse refractory follicular non-Hodgkin lymphoma .</brief_summary>
	<brief_title>Fludarabine , Velcade Rituximab Relapsed Refractory Follicular Non-Hodgkin Lymphoma</brief_title>
	<detailed_description>OUTLINE : This multi-center study . - Fludarabine 25 mg/m2 IV 30 minute , Days 1 , 2 , 4 - Velcade ( give fludarabine ) 1.3 mg/m2 IV push 3 5 second , Days 1 , 4 , 8 , 11 - Rituximab ( give Velcade ) 375 mg/m2 IV piggyback , Day 1 - Cycle = 28 day ; max 6 cycle ECOG Performance Status : 0-2 Life Expectancy : Not specify Hematopoietic : - Absolute neutrophil count ( ANC ) ≥ 1.5 K/mm3 ( ANC &gt; 0.5 K/mm3 know lymphomatous involvement bone marrow ) . - Platelets ≥ 100 K/mm3 ( Platelets &gt; 50 K/mm3 know lymphomatous involvement bone marrow ) . Hepatic : - Total bilirubin ≤1.5 ULN - Aspartate aminotransferase ( AST , SGOT ) ≤ 2.5 x ULN - Alanine aminotransferase ( ALT , SGPT ) ≤ 2.5 x ULN Renal : - Creatinine &lt; 1.5 x institutional upper limit ( ULN ) creatinine clearance ≥ 50 cc/min Cardiovascular : - No myocardial infarction within 6 month prior enrollment - No heart failure per New York Heart Association Classification III IV - No severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Must histologically confirm Follicular NonHodgkin Lymphoma ( Grade I , II , IIIa ) Must measurable disease define least one lesion accurately measure least one dimension ( long diameter record ≥2 cm conventional technique &gt; 1 cm spiral CT scan ) obtain image within 30 day prior registration protocol therapy . Must receive least one prior therapeutic regimen , three prior regimen conventional cytotoxic therapy . NOTE : Prior recipient stem cell transplantation include , preparative cytoreductive highdose therapy count collectively one prior therapy . Must cytotoxic chemotherapy least four week prior registration protocol therapy ( 6 week BCNU mitomycin C ) . Patients allow received one course prior radioimmunotherapy ( RIT : either tositumomab ibritumomab ) . NOTE : Radioimmunotherapy must complete least 12 week prior registration protocol therapy recovery baseline ANC platelet . Prior fludarabine , Velcade rituximab allow long therapy complete least 30 day prior registration protocol therapy . Patients may refractory ( define respond demonstrate progressive disease &lt; 6 month ) prior rituximab . Patients may refractory prior fludarabine Velcade . Females childbearing potential male must willing use effective method contraception ( hormonal barrier method birth control ; abstinence ) time consent sign 30 day follow protocol therapy . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . Females childbearing potential must negative serum pregnancy test within 7 day prior prior registration protocol therapy . NOTE : Patients consider child bear potential unless surgically sterile ( undergone hysterectomy , bilateral tubal ligation , bilateral oophorectomy ) postmenopausal ( menses least 12 month ) . Females must breastfeed . Males must agree use acceptable method contraception duration study . No current active CNS metastasis . Patients neurological symptom must undergo head CT scan brain MRI exclude brain metastasis within 7 day prior registration protocol therapy . NOTE : Patients treat brain metastasis must steroids taper stable dos steroid complete radiation least 30 day prior registration protocol therapy . No prior malignancy allow except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , Gleason ≤ grade 6 prostate cancer , cancer subject diseasefree least 3 year . No treatment investigational agent within 30 day prior registration protocol therapy . Prior radiation therapy allow &lt; 25 % bone marrow . NOTE : No radiation therapy within 30 day prior registration protocol therapy . No clinically significant infection judge treat investigator . No active HIV , hepatitis B hepatitic C infection . No cerebrovascular accident ( CVA ) within 6 month study enrollment . No psychiatric illness/social situation would limit compliance study requirement . No history hypersensitivity Velcade , boron mannitol . No peripheral neuropathy grade &gt; 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>